IDF21-0338 Results of Randomized Double Blind Phase III trial of FDC of Remogliflozin Etabonate and Teneligliptin in T2DM patients. (April 2022) - Balamurgan, R.; Mohan, B.; Kodgule, R.; Tandon, M.; Pendse, A.; Khaladkar, K.; Sharath, R.; Katare, S.; Suryawanshi, S.; Barkate, H.